REGISTER NOW
SUBMIT ABSTRACT
ARUHEAL
7th World Cancer Congress - 2022 | Bangalore 7th World Cancer Congress - 2022 | Bangalore 7th World Cancer Congress - 2022 | Bangalore
Early Bird Registration Closes:11th December, 2021 1st Phase Abstract Submission Closes: 15th June, 2022

EMIL VON BEHRING MEMORIAL AWARD


Emil von Behring was a German physiologist who received the 1901 Nobel Prize in Physiology or Medicine, the first one awarded in that field, for his discovery of a diphtheria antitoxin. He was widely known as a "saviour of children," as diphtheria used to be a major cause of child death. His work with the disease, as well as tetanus, has come to bring him most of his fame and acknowledgment. He was honored with Prussian nobility in 1901, henceforth being known by the surname "von Behring."

In 1890 he published an article with Kitasato Shibasaburō reporting that they had developed "antitoxins" against both diphtheria and tetanus. They had injected diphtheria and tetanus toxins into guinea-pigs, goats and horses; when these animals developed immunity, they derived antitoxins (now known to contain antibodies) from their serum. This process would be called serum therapy by him at the time as he described it as a way to induce permanent immunity or "to stimulate the body's internal disinfection". These antitoxins could protect against and cure the diseases in non-immunized animals. In 1892 he started the first human trials of the diphtheria antitoxin, but they were unsuccessful. Successful treatment started in 1894, after the production and quantification of antitoxin had been optimized. During 1894, Behring was also awarded the Cameron Prize for Therapeutics of the University of Edinburgh.

Behring won the first Nobel Prize in Physiology or Medicine in 1901 for the development of serum therapies against diphtheria. He was elected a Foreign Honorary Member of the American Academy of Arts and Sciences in 1902. In 1904 he founded the Behringwerke in Marburg, a company to produce antitoxins and vaccines. At the International Tuberculosis Congress in 1905 he announced that he had discovered "a substance proceeding from the virus of tuberculosis." This substance, which he designated "T C," plays the important part in the immunizing action of his "bovivaccine", which prevents bovine tuberculosis. He tried unsuccessfully to obtain a protective and therapeutic agents for humans.

Eligibility
  • Senior Scientist or Researcher e.g. Senior Faculty, Dean, Senior Scientist) are the focus of this event.
  • The topic must fit into scientific sessions of the conference.
  • Each individual participant is allowed to submit only one paper (as first author or co-author).
  • All authors should have senior position or faculty position.
  • Participants should be above the age of 40 years.
  • Actively distribute information and promote the benefits of education and career matters.


Criteria for Selection
  • Showcase your research through oral presentations and its impact to the Panel Member.
  • Impact of the Research Work.
  • Importance of the Research work to the socity.
  • New Innovation in the Research Work


Awards & Rewards
  • The top 2 nominee will be awarded with Emil von Behring Memorial Award at the end of the conference.


For Nomination Kindly write a mail to the Conference Secretariat at [email protected] and kindly attached the below mentioned documents.
  • Brief CV(Kindly mention atleast 2 reference)
  • Abstact for his/her speeh during the summit.
  • Last 2 Publication Research Work
  • 1 Copy of HD Photograph




7th World Congress on Drug Discovery and Development - 2022 | Bangalore


CONTACT US AT


Conference Secretariat
INDIA
ARJYOPA HEALTHCARE
#2 RBC Road, Gora Bazar, Dumdum Cantonment,
Kolkata - 700028, West Bengal, India
Ph: +91 7002-412-271
Whatsapp: +91 7002-412-271


UNITED STATES
ARJYOPA HEALTHCARE
16192 Coastal Hwy., Lewes, DE 19958, US
Ph: +1 (315) 830-2544


WRITE TO US
7th World Cancer Congress - 2022 | Bangalore
Copyright © 2016 - 2022@IPC@Arjyopa Healthcare All Rights Reserved